ABVC BIOPHARMA, INC. ABVC
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
3/9
Piotroski F — financial health
-13.52
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $296,000 | -$7.9M | — | — | $13.3M |
| 2024 | $200,000 | -$4.9M | $508,826 | — | $723,959 |
| 2023 | $152,430 | -$7.8M | -$149,607 | -$4.2M | $1.3M |
| 2022 | $969,783 | -$16.4M | $683,368 | -$7.5M | $3.2M |
| 2021 | $355,797 | -$12.8M | $350,711 | -$7.6M | $8.9M |
| 2020 | $483,045 | -$10.6M | $464,329 | — | $2.7M |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -13.52 (distress)
- Working capital / assets -0.174
- Retained earnings / assets -3.649
- EBIT / assets -0.34
- Equity / liabilities 1.713
Source: SEC EDGAR filings · CIK 0001173313 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.